Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Mallinckrodt
Baxter
Johnson and Johnson
Merck

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

LIALDA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Lialda patents expire, and what generic alternatives are available?

Lialda is a drug marketed by Shire and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in seventeen countries.

The generic ingredient in LIALDA is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

Drug patent expirations by year for LIALDA
Drug Prices for LIALDA

See drug prices for LIALDA

Drug Sales Revenue Trends for LIALDA

See drug sales revenues for LIALDA

Recent Clinical Trials for LIALDA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NorthShore University HealthSystemPhase 2
ShirePhase 1
Shire Human Genetic Therapies, Inc.Phase 3

See all LIALDA clinical trials

Recent Litigation for LIALDA

Identify potential future generic entrants

District Court Litigation
Case NameDate
Shire Development, LLC v. Watson Laboratories, Inc. - FL2016-04-04
SHIRE PHARMACEUTICAL DEVELOPMENT INC. v. AMNEAL PHARMACEUTICALS LLC2015-04-22
Shire Development, LLC v. Mylan Pharmaceuticals, Inc.2012-05-25

See all LIALDA litigation

PTAB Litigation
PetitionerDate
Coalition For Affordable Drugs II LLC2015-04-01

See all LIALDA litigation

Pharmacology for LIALDA
Drug ClassAminosalicylate
Synonyms for LIALDA
1764-EP2272825A2
1764-EP2275420A1
2-Hydroxy-5-aminobenzoic acid
24215-EP2289518A1
24215-EP2295053A1
24215-EP2295409A1
24215-EP2314574A1
24215-EP2314590A1
3-amino-6-hydroxybenzoic acid
3-carboxy-4-hydroxyaniline
35589-28-7 (mono-hydrochloride salt)
3amino-6-hydroxybenzoic acid
4-14-00-02058 (Beilstein Handbook Reference)
4Q81I59GXC
5-?Aminosalicylic Acid (Mesalazine)
5-Amino 2-hydroxy benzoic acid
5-Amino Salicylic Acid
5-amino-2-hydroxy-benzoic acid
5-Amino-2-hydroxybenzoic acid
5-Amino-2-hydroxybenzoic acid 97%
5-amino-2-hydroxybenzoic acid,5-Aminosalicylic acid
5-Amino-2-hydroxybenzoic acid; 5-AS; Mesalamine; 5-ASA
5-amino-2-hydroxybenzoicacid
5-amino-salicylic acid
5-Aminosalicyclic acid
5-Aminosalicylate
5-Aminosalicylic acid
5-Aminosalicylic acid, >=99%
5-Aminosalicylic acid, 95%
5-Aminosalicylic acid, 99%
5-Aminosalicylic acid, analytical standard
5-Aminosalicylic Acid, Purified
5-Aminosalicylic acid, tablet
5-Aminosalicylicacid
5-AS
5-ASA
61513-32-4
6291-36-7 (hydrochloride)
89-57-6
90701-EP2371811A2
A0317
A3613/0153179
AB00374979
AB00374979_11
AB00374979_12
AB00374979-09
AB00374979-10
AB1001921
AC-2764
AC1L1HCS
AC1Q51L9
ACMC-1BKFR
AI3-15564
AJ-08068
AJG-501
AK-72925
AKOS000118959
AM20060091
AN-874
ANW-39326
Apriso
Apriso (TN)
ARONIS23914
Asacol
Asacol (TN)
Asacol HD
Asacolitin
BBL013046
BCP05326
BCP9000175
BDBM60918
Benzoic acid, 5-amino-2-hydroxy-
BIDD:GT0811
BP-13074
BPBio1_001164
BR-72925
BRN 2090421
BSPBio_001058
C07138
Canasa
Canasa (TN)
CAS-89-57-6
CCG-100829
CCRIS 7334
CHEBI:6775
CHEMBL704
cid_4075
Claversal
cMAP_000045
CPD000145728
CS-2219
CTK3E8105
D00377
DB00244
Delzicol
Delzicol (TN)
DSSTox_CID_4506
DSSTox_GSID_24506
DSSTox_RID_77435
DTXSID5024506
EC 201-919-1
EINECS 201-919-1
F1918-0003
FC1035
Fisalamine
FT-0619950
GTPL2700
HMS1571E20
HMS2051M21
HMS2090I09
HMS2098E20
HMS3393M21
HMS3649K15
HMS3651M15
HMS3715E20
HS-0100
HSDB 7512
HY-15027
I06-0488
Iialda
InChI=1/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11
KB-196569
KB-196728
KBio2_002425
KBio2_004993
KBio2_007561
KBio3_002904
KBioGR_002425
KBioSS_002431
KBOPZPXVLCULAV-UHFFFAOYSA-N
KS-00000CC5
KS-000048PQ
KSC448C0L
Lialda (TN)
Lixacol
LS-1894
LS11426
M-7246
m-Aminosalicylic acid
MAX-002
MCULE-5752745805
MD-0901
mesalamine
Mesalamine (Lialda)
Mesalamine (TN)
mesalamine (USAN)
Mesalamine (USP)
Mesalamine [USAN:USP]
Mesalamine [USAN]
Mesalamine, Pharmaceutical Secondary Standard; Certified Reference Material
Mesalamine, United States Pharmacopeia (USP) Reference Standard
Mesalamine|||Mesalazine
Mesalazina
Mesalazina [Spanish]
Mesalazine
Mesalazine (JAN/INN)
Mesalazine [INN]
Mesalazine for system suitability, European Pharmacopoeia (EP) Reference Standard
Mesalazine MMX
Mesalazine, European Pharmacopoeia (EP) Reference Standard
Mesalazinum
Mesalazinum [Latin]
Mesasal
Mesavance
Mesavancol
meta-Aminosalicylic Acid
Mezavant
Mezavant XL
MFCD00007877
MFCD00007877 (98%)
MLS000758287
MLS001424012
MolPort-001-641-024
NC00079
NCGC00016344-01
NCGC00016344-02
NCGC00016344-03
NCGC00016344-04
NCGC00016344-05
NCGC00016344-07
NCGC00090934-01
NCGC00090934-02
NCGC00257142-01
NCGC00259159-01
NSC 38877
NSC-38877
NSC-759301
NSC38877
NSC759301
Oprea1_847633
p-Aminosalicylsaeure
p-Aminosalicylsaeure [German]
Pentasa
Pentasa (TN)
Pharmakon1600-01505993
Prestwick0_001069
Prestwick1_001069
Prestwick2_001069
Prestwick3_001069
PubChem17623
Q-201355
Rowasa
Rowasa (TN)
RP21708
RTR-032941
s1681
SALICYLIC ACID, 5-AMINO-
Salofalk
Salofalk Granu-Stix
SAM001247020
SBB052617
SC-15695
SCHEMBL18038934
SCHEMBL31297
sfRowasa
Sfrowasa (TN)
SMR000145728
SPBio_002969
SPD 476
SPD-476
SPD-480
SR-01000763486
SR-01000763486-3
SR-01000763486-4
SR-01000763486-9
ST2411704
ST4109571
STK301678
SW197303-4
SY002854
Tox21_110384
Tox21_110384_1
Tox21_201610
Tox21_303125
TR-032941
TRA0073805
UNII-4Q81I59GXC
WLN: ZR DQ CVQ
Z-206
Z57127471
ZINC1688
Paragraph IV (Patent) Challenges for LIALDA
Tradename Dosage Ingredient NDA Submissiondate
LIALDA TABLET, DELAYED RELEASE;ORAL mesalamine 022000 2009-12-16

US Patents and Regulatory Information for LIALDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire LIALDA mesalamine TABLET, DELAYED RELEASE;ORAL 022000-001 Jan 16, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKinsey
Medtronic
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.